Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.49 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.49 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.49 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24278620 | 0.85 | BCHE (0.46) | CES2CES1LGALS9LGALS8LGALS1 | |
| SCHEMBL24278827 | 0.84 | LGALS9 (0.43) | CES2CES1LGALS9LGALS8LGALS1 | |
| SCHEMBL26705642 | 0.80 | CHRNA7 (0.53) | MEN1KMT2ALMNA | |
| SCHEMBL27138259 | 0.80 | CHRNA7 (0.53) | MEN1KMT2ALMNA | |
| SCHEMBL11067038 | 0.80 | HRH3 (0.52) | CES2CES1LGALS9LGALS8LGALS1 | |
| SCHEMBL24278810 | 0.80 | CES2 (0.45) | CES2CES1LGALS9LGALS8LGALS1 | |
| SCHEMBL24278717 | 0.80 | SLC6A4 (0.45) | CES2CES1LGALS9LGALS8LGALS1 | |
| SCHEMBL27105762 | 0.80 | CES2 (0.45) | CES2CES1LGALS9LGALS8LGALS1 | |
| SCHEMBL27105248 | 0.80 | CES2 (0.52) | CES2CES1LGALS9LGALS8LGALS1 | |
| SCHEMBL24278705 | 0.80 | BCHE (0.42) | CES2CES1LGALS9LGALS8LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067764-A1 | SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER | MITSUI CHEMICALS, INC. (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240067764-A1 | SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER | MITSUI CHEMICALS, INC. (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240067597-A1 | ESTER COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240067597-A1 | ESTER COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2024-02-29 | — | — | US | disclosed |
| EP-4269450-A1 | SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER | Mitsui Chemicals, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| EP-4265593-A1 | ESTER COMPOUND | Mitsui Chemicals, Inc. (JP) | 2023-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067597-A1 | ESTER COMPOUND | PPT1, GPER1, TCP1 | CES2 105/4885CES1 65/4885LGALS9 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.